XML 24 R13.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Nov. 30, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 7: SUBSEQUENT EVENTS At the December 10, 2020 board meeting, the Board of Directors approved the grant of 213,616 options to purchase shares of the Company’s common stock to officers, directors and certain employees. The options are exercisable by outside board members one year from date of grant and for officers and employees one-quarter per year with the first quarter vesting one year from date of grant. The options will be at the exercise price of $6.36 per share and expire ten years from date of grant. During December 2020, the Company filed the necessary paperwork with Medical Device Safety Service who then notified the competent authority in Germany to attain CE Mark in the EU for the Company’s COVID-19 antigen test that uses a nasal swab to collect a person’s nasal fluid sample to detect if the person has COVID-19 antigen in their system, which can indicate that the person has recently been infected with the COVID-19 virus and may still be infectious to others. This nasal swab antigen test received CE clearance on January 8, 2021, and is now available for sale in the EU. The Company has received an initial order for over $1 million of these tests and is in the process of filling this order.